石药集团欧意药业有限公司药品申请临床试验默示许可获受理

金融界2025-04-18

4月18日，据CDE官网消息，石药集团欧意药业有限公司联合申请药品“普卢格列汀二甲双胍缓释片（Ⅰ）”，获得临床试验默示许可，受理号CXHL2500185。公示信息显示，药品“普卢格列汀二甲双胍缓释片（Ⅰ）”适应症：适用于成人 2 型糖尿病患者：本品配合饮食和运动治疗，用于二甲双胍单药治疗控制不佳或正在接受普卢格列汀与二甲双胍联合治疗。石药集团欧意药业有限公司，成立于2001年，位于石家庄市，是一家...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2528308722?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-18 13:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2528308722","market":"us","top_or_hot":-1,"title":"石药集团欧意药业有限公司药品申请临床试验默示许可获受理","media":"金融界","content":"<div>\n<p>4月18日，据CDE官网消息，石药集团欧意药业有限公司联合申请药品“普卢格列汀二甲双胍缓释片（Ⅰ）”，获得临床试验默示许可，受理号CXHL2500185。公示信息显示，药品“普卢格列汀二甲双胍缓释片（Ⅰ）”适应症：适用于成人 2 型糖尿病患者：本品配合饮食和运动治疗，用于二甲双胍单药治疗控制不佳或正在接受普卢格列汀与二甲双胍联合治疗。石药集团欧意药业有限公司，成立于2001年，位于石家庄市，是一家...</p>\n\n<a href=\"https://finance.jrj.com.cn/2025/04/18134049650524.shtml\">网页链接</a>\n\n</div>\n","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石药集团欧意药业有限公司药品申请临床试验默示许可获受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石药集团欧意药业有限公司药品申请临床试验默示许可获受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-18 13:40 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.jrj.com.cn/2025/04/18134049650524.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4月18日，据CDE官网消息，石药集团欧意药业有限公司联合申请药品“普卢格列汀二甲双胍缓释片（Ⅰ）”，获得临床试验默示许可，受理号CXHL2500185。公示信息显示，药品“普卢格列汀二甲双胍缓释片（Ⅰ）”适应症：适用于成人 2 型糖尿病患者：本品配合饮食和运动治疗，用于二甲双胍单药治疗控制不佳或正在接受普卢格列汀与二甲双胍联合治疗。石药集团欧意药业有限公司，成立于2001年，位于石家庄市，是一家...</p>\n\n<a href=\"https://finance.jrj.com.cn/2025/04/18134049650524.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1951186391.HKD","symbol_name":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","start_time":0,"source_url":"https://finance.jrj.com.cn/2025/04/18134049650524.shtml","article_id":"2528308722","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2528308722","pubTimestamp":1744954838,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"4月18日，据CDE官网消息，石药集团欧意药业有限公司联合申请药品“普卢格列汀二甲双胍缓释片（Ⅰ）”，获得临床试验默示许可，受理号CXHL2500185。通过天眼查大数据分析，石药集团欧意药业有限公司共对外投资了11家企业，参与招投标项目5000次，知识产权方面有商标信息198条，专利信息197条，此外企业还拥有行政许可746个。主要股东信息显示，石药集团欧意药业有限公司由石药集团恩必普药业有限公司持股100%。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","BK1515":"抗疫概念","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","03347":"泰格医药","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","BK1583":"高瓴概念","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","BK1521":"挪威政府全球养老基金持仓","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","IE0008368742.USD":"首域中国增长基金I Acc","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","01093":"石药集团","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK1191":"制药","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC"},"translate_title":"CSPC Ouyi Pharmaceutical Co., Ltd. 's drug application for clinical trial implied license was accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1,"03347":1},"content_text":"4月18日，据CDE官网消息，石药集团欧意药业有限公司联合申请药品“普卢格列汀二甲双胍缓释片（Ⅰ）”，获得临床试验默示许可，受理号CXHL2500185。公示信息显示，药品“普卢格列汀二甲双胍缓释片（Ⅰ）”适应症：适用于成人 2 型糖尿病患者：本品配合饮食和运动治疗，用于二甲双胍单药治疗控制不佳或正在接受普卢格列汀与二甲双胍联合治疗。石药集团欧意药业有限公司，成立于2001年，位于石家庄市，是一家以从事医药制造业为主的企业。企业注册资本29800万人民币，实缴资本29800万人民币。通过天眼查大数据分析，石药集团欧意药业有限公司共对外投资了11家企业，参与招投标项目5000次，知识产权方面有商标信息198条，专利信息197条，此外企业还拥有行政许可746个。主要股东信息显示，石药集团欧意药业有限公司由石药集团恩必普药业有限公司持股100%。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2528308722","isCrawlerRequest":true}